RBC Capital Downgrades OncoGenex Pharmaceuticals (OGXI) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Take-Two stock drops as GTA 6 leaks continue
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- Goldman Sachs raises humanoid robot forecast, sees auto role
Needham & Company Downgrades OncoGenex Pharmaceuticals (OGXI) to Hold
April 28, 2014 1:46 PM EDTNeedham & Company downgraded OncoGenex Pharmaceuticals (NASDAQ: OGXI) from Strong Buy to Hold with a price target of $14.00.
Analyst Chad Messer comments, "OncoGenex reported negative top line data from the pivotal SYNERGY trial testing custersin on top of 1st line chemotherapy with docetaxel in patients... More
OncoGenex Pharmaceuticals (OGXI), Teva (TEVA) Said Phase III SYNERGY Trial Did Not Meet Primary Endpoint
April 28, 2014 7:05 AM EDTTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) and OncoGenex Pharmaceuticals, Inc.(NASDAQ: OGXI) today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone... More
